Infectious diseases now · 2025
Low-level primary clarithromycin resistance of Helicobacter pylori in Reunion Island.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Charazac Arthur, Delage Raphael, Pichon Maxime, Kamus Laure, Pichard Benoit, Peyret-Moreau Laura, Belmonte Olivier, Miltgen Guillaume, Burucoa Christophe
Аннотация
INTRODUCTION: The increasing resistance of Helicobacter pylori to clarithromycin leads to an ongoing adaptation of empirical first-line treatment for H. pylori infections.
PATIENTS AND METHODS: Prospective study (2022-2023) of 364 patients with no previous treatment for H. pylori infection, addressed for gastroduodenal endoscopy to the University Hospital of Reunion Island.
RESULTS: PCR tests (AllplexTMH. pylori & ClariRAssay, Seegene) performed on gastric biopsy samples detected H. pylori DNA in 100 samples (100/364; 27.5 %) and mutations conferring resistance to clarithromycin in 10 of the positive samples (10/100; 10 %). Prevalence of resistance determined by MICs (E-test method) was 41.2 % for metronidazole, 13.2 % for levofloxacin, 8.8 % for clarithromycin. No resistance was detected for tetracycline, rifampicin, and amoxicillin.
CONCLUSION: The prevalence of primary clarithromycin-resistant H. pylori in Reunion Island is below 15 %. Recommendation for the standard clarithromycin-based triple therapy as a first-line treatment can thus be maintained, even though antimicrobial susceptibility testing seems preferable.
PATIENTS AND METHODS: Prospective study (2022-2023) of 364 patients with no previous treatment for H. pylori infection, addressed for gastroduodenal endoscopy to the University Hospital of Reunion Island.
RESULTS: PCR tests (AllplexTMH. pylori & ClariRAssay, Seegene) performed on gastric biopsy samples detected H. pylori DNA in 100 samples (100/364; 27.5 %) and mutations conferring resistance to clarithromycin in 10 of the positive samples (10/100; 10 %). Prevalence of resistance determined by MICs (E-test method) was 41.2 % for metronidazole, 13.2 % for levofloxacin, 8.8 % for clarithromycin. No resistance was detected for tetracycline, rifampicin, and amoxicillin.
CONCLUSION: The prevalence of primary clarithromycin-resistant H. pylori in Reunion Island is below 15 %. Recommendation for the standard clarithromycin-based triple therapy as a first-line treatment can thus be maintained, even though antimicrobial susceptibility testing seems preferable.